Agreement - June 4, 2014
AstraZeneca and Episentec in research agreement
The two companies have signed a research collaboration agreement for the development and implementation of improved methodology for early screening of potential new drug molecules. The research project will be aimed at an undisclosed drug target protein and will be utilizing the proprietary Label-Enhanced SPR biosensor technology of Episentec. Under the agreement, AstraZeneca will supply target protein and […]
Agreement - May 7, 2014
Sectra signs agreement with University Hospitals in Cleveland
The University Hospitals are to invest in dose monitoring solution from Sectra as part of large multi-year agreement. The order includes a radiation dose monitoring solution and a five-year extension of the hospital’s service and support contract for its medical IT solutions provided by Sectra. University Hospitals is one of Sectra’s largest customers in the US as […]
Agreement - April 25, 2014
Bactiguard expands in Latin America
The company has signed a distribution agreement with Promedon allowing the company to sell Bactiguard’s complete portfolio of medical devices in Argentina, Brazil, Chile and Mexico. Under the agreement, Promedon will be marketing and selling Bactiguard’s complete portfolio for infection control, including urinary, intravenous and respiratory catheters in the four countries. According to Bactiguard, the company has already secured […]
Agreement - April 14, 2014
Moberg Pharma acquires treatment project
Moberg Pharma has acquired the global rights to a novel topical formulation for the treatment of oral pain. The company has announced that it has entered into a definitive agreement with Danish Oracain II Aps to acquire all assets as well as global rights to a novel and patent pending oral formulation of the proven […]
Agreement - April 4, 2014
Sobi enters partnership with Tigenix
Sobi has acquired the licencing rights to market and distribute Tigenix’s product ChondroCelect.
Agreement - April 1, 2014
Index Pharmaceuticals signs deal with Almirall
The two companies have entered into a license agreement for European rights of the phase III drug candidate Kappaproct.